Rhythm pharmaceuticals announces five new data presentations at obesityweek® 2024

-- real-world data showed mean bmi decrease of 12.8% in adult patients with acquired hypothalamic obesity (n=8) at three months on setmelanotide therapy; mean bmi decrease of 21.3% in patients (n=5) who reached six months -- -- greater reduction in fat mass (29.7%) versus reduction in lean muscle mass (7.7%) reported from phase 2 trial extension in patients with acquired hypothalamic obesity (n=11) after 12 months --
BMI Ratings Summary
BMI Quant Ranking